北京若生智能科技有限公司
Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · 疫苗 · 疫苗

什么是 yellow fever vaccine？

yellow fever vaccine 是一种疫苗，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Arilvax
公司Novartis AG
药物类别疫苗, 大分子
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Novartis AG

治疗适应症

yellow fever vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsYellow fever✓ Approved

相关研究文献

PubMedDiseases (Basel, Switzerland)2026-10-26

Tetanus in Serbia, 2015-2025: Epidemiological Overview and Lessons from Two Pediatric Cases.

Kovacevic Gordana G, Stijovic Vesna V, Kovacevic Branko B, Parezanovic Miro M et al.

Tetanus is a vaccine-preventable disease that has become rare in countries with sustained immunization programs. However, unvaccinated children remain at risk of severe disease. We provide an epidemiological overview of tetanus in Serbia and describe two cases of generalized tetanus in children. We retrospectively reviewed tetanus surveillance data and immunization coverage reports in Serbia for 2015-2025. Tetanus cases were recorded under ICD-10 code A35. We analyzed demographics, incidence, outcomes, case-fatality, and tetanus-containing vaccine coverage. Two pediatric cases were reviewed for clinical presentation, diagnostic challenges, management, and outcomes. Fourteen tetanus cases were reported during 2015-2025 (annual incidence, 0-0.06 per 100,000 population), including two children. Most cases occurred among women aged >60 years; the overall case-fatality proportion was 42.9%. Primary vaccination coverage ranged from 90.8% to 95.1%, while recommended revaccination coverage remained below the 95% target. Both pediatric patients had received only BCG and hepatitis B vaccination at birth with no subsequent routine immunization due to parental neglect or refusal. The 18-month-old boy presented with fever, otorrhea, and recurrent episodes of generalized stiffening and was initially evaluated for meningoencephalitis. The emergence of trismus, opisthotonus, and neck muscle rigidity led to the diagnosis of tetanus. The 6-year-old boy presented with odynophagia and involuntary tongue biting, followed by progressive trismus and limb spasms. Tetanus was suspected based on the clinical findings and absent immunization. He developed respiratory failure and autonomic instability. Both patients recovered following tetanus immunoglobulin, antimicrobial therapy, and supportive care. Although tetanus remains rare in Serbia and predominantly affects older adults, unvaccinated children remain at risk of severe disease. Atypical presentations may delay diagnosis, emphasizing the importance of early recognition and timely treatment. Maintaining high vaccination coverage and ensuring catch-up immunization remain essential for prevention.

PMID 42930012
阅读全文 →
PubMedWellcome open research2026-10-26

The genome sequence of the Purple-barred Yellow, Lythria purpuraria (Linnaeus, 1758) (Lepidoptera: Geometridae).

Vila Roger R, Toro-Delgado Eric E, Wright Charlotte J CJ, Meier Joana I JI et al.

We present a genome assembly from a male specimen of Lythria purpuraria (Purple-barred Yellow; Arthropoda; Insecta; Lepidoptera; Geometridae). The assembly contains two haplotypes with total lengths of 241.87 megabases and 241.80 megabases. Most of the haplotype 1 assembly (99.57%) was scaffolded into 31 chromosomal pseudomolecules, including the Z sex chromosome. Haplotype 2 was assembled to scaffold level. The mitochondrial genome has also been assembled, with a length of 18.13 kilobases. This work is part of Project Psyche, a collaborative programme generating genomes for European butterflies and moths.

PMID 42928717
阅读全文 →
PubMedBMC infectious diseases2026-10-26

Azithromycin versus ceftriaxone for uncomplicated typhoid fever in children: a systematic review and meta-analysis of randomized controlled trials.

Manzoor Muhammad Umair MU, Anwar Aqsa A, Owais Muhammad M, Umar Syed S et al.

Typhoid fever caused by Salmonella enterica serovar Typhi remains a major cause of febrile illness among children in low- and middle-income countries, particularly in South and Southeast Asia. The increasing emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has substantially limited available treatment options and highlighted the need for effective oral therapies. Azithromycin and ceftriaxone are commonly used for uncomplicated typhoid fever in children; however, evidence comparing their efficacy and safety remains limited. To compare the efficacy and safety of azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children through a systematic review and meta-analysis of randomized controlled trials. A comprehensive literature search was conducted in PubMed, the Cochrane Library, ClinicalTrials.gov, Google Scholar, and WHO ICTRP from inception to April 2026 in accordance with PRISMA 2020 guidelines. Randomized controlled trials comparing azithromycin with ceftriaxone in children under 18 years of age with uncomplicated typhoid fever were included. The primary outcome was the clinical cure rate. Secondary outcomes included fever clearance time, microbiological cure, relapse, and adverse events. Data extraction and risk of bias assessment using the Cochrane Risk of Bias 2 tool were performed independently by two reviewers. Meta-analysis was conducted using a random-effects model, and heterogeneity was assessed using the I² statistic. Six randomized controlled trials involving 492 children (azithromycin = 244; ceftriaxone = 248) were included. All studies were open-label trials conducted in Egypt, India, Pakistan, and Bangladesh. Overall risk of bias was judged to be of some concern, mainly due to the open-label study design. Meta-analysis showed no significant difference between azithromycin and ceftriaxone in clinical cure rate (RR = 0.98, 95% CI 0.93-1.03; P = 0.43) or fever clearance time. Similarly, microbiological cure and adverse event profiles were similar across groups but could not be formally pooled due to heterogeneous reporting. However, azithromycin was associated with fewer relapses than ceftriaxone, though this finding should be interpreted with caution given the low certainty of the evidence. The certainty of evidence was very low for fever clearance and low for the relapse rate. Heterogeneity varied across outcomes, with the highest for fever clearance time. Azithromycin appears to have comparable efficacy and safety to ceftriaxone for the treatment of uncomplicated typhoid fever in children, with a trend toward fewer relapses that warrants cautious interpretation. Its oral administration may provide a practical alternative to parenteral ceftriaxone in endemic settings. Further large-scale randomized trials with standardized outcome reporting are needed to strengthen the current evidence base. Not applicable. PROSPERO Protocol Number: CRD420261383999. LINK: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261383999 .

PMID 42928111
阅读全文 →
PubMedAquaculture nutrition2026-10-26

Dietary Myo-Inositol Improves Growth Performance and Glycolipid Metabolism in Yellow River Carp (Cyprinus carpio haematopterus) Fed High-Carbohydrate-High-Fat Diets: Involvement of PI3K/Akt and FXR/SHP Pathways.

Yan Xiao X, Long Xin X, Qiao Rumeng R, Pang Peng P et al.

High-carbohydrate-high-fat (HCHF) diets often induce glycolipid metabolism disorders, Hepatosomatic fat deposition, and compromised growth in fish. Myo-inositol (MI) is a known metabolic regulator, yet its specific mechanism in mitigating HCHF-induced metabolic stress in Yellow River carp remains unclear. This study investigated the effects of dietary MI on growth, glycolipid metabolism, and bile acid signaling in fish fed HCHF diets. Six experimental diets were formulated: a control diet, an HCHF diet, and the HCHF diet supplemented with graded levels of MI (125, 250, 500, and 1000 mg·kg-1). After a 9-week feeding trial, results showed that MI supplementation dose-dependently improved growth performance (FBW, WGR, and SGR) and feed utilization (FCR), while significantly reducing the hepatosomatic index (HSI). Physiologically, MI reduced serum glucose and triglycerides (TGs), as well as hepatopancreatic total cholesterol (T-CHO) and TG levels, while elevating high-density lipoprotein cholesterol (HDL-C), suggesting enhanced lipid transport capacity. Regarding glycolipid metabolism, MI promoted glycolysis by increasing hk and pfk mRNA expression, while suppressing gluconeogenesis (pepck) and lipogenesis (fas, pparγ). These metabolic changes were accompanied by alleviated hepatocyte vacuolation and morphological abnormalities, with reduced hepatocellular vacuolation and lipid deposition in HCHF-fed fish. Mechanistically, bile acid metabolism and phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathways participated extensively and served important roles in the action of MI. Based on comprehensive analysis of growth and physiological indicators, the optimal MI supplementation level in the HCHF diet is recommended as 230-475 mg·kg-1. In conclusion, MI alleviates HCHF diet-induced metabolic disorders and hepatopancreatic morphological abnormalities in Yellow River carp, and this effect is associated with the PI3K/Akt and farnesoid X receptor (FXR)/SHP (small heterodimer partner) pathways, providing a theoretical basis for functional feed development for fish.

PMID 42928767
阅读全文 →
PubMedCancer discovery2026-10-26

First mRNA Cancer Vaccine Succeeds in Phase III Trial.

Adding the mRNA-based individualized neoantigen vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death by 42%, according to the results of the phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

PMID 42929716
阅读全文 →
PubMedAnimal health research reviews2026-10-26

Innovative vaccine strategies for sustainable control and eradication of peste des petits ruminants virus.

Bello Muhammad Bashir MB, Hameed Sodiq A SA, Abdullahi Adama Musa AM, Lawal Nafi'u N et al.

PMID 42929676
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多yellow fever vaccine